Your browser doesn't support javascript.
loading
A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
Del Rosso, Mario; Fibbi, Gabriella; Laurenzana, Anna; Margheri, Francesca; Chillà, Anastasia.
Affiliation
  • Del Rosso M; Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy. Electronic address: mario.delrosso@unifi.it.
  • Fibbi G; Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
  • Laurenzana A; Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
  • Margheri F; Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
  • Chillà A; Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
J Invest Dermatol ; 141(11): 2566-2568, 2021 11.
Article in En | MEDLINE | ID: mdl-34688409
ABSTRACT
In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasminogen Activator Inhibitor 1 / Melanoma Limits: Humans Language: En Journal: J Invest Dermatol Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasminogen Activator Inhibitor 1 / Melanoma Limits: Humans Language: En Journal: J Invest Dermatol Year: 2021 Document type: Article